Pemvidutide showed significant reductions in inflammatory lipids, supporting its potential benefits for metabolic dysfunction-related conditions.Quiver AI SummaryAltimmune, Inc. announced favorable results...
In a remarkable turn of events, Altimmune (NASDAQ: ALT) witnessed a staggering 27% surge in its stock price this morning, fueled by promising clinical data from its Phase 2 trials and heightened investor...
Altimmune is betting big on its investigational metabolic diseases candidate pemvidutide.
The new hire’s background includes CFO roles at several biotech firms acquired in high-profile deals, such as Sirna Therapeutics (acquired by Merck) and ILEX Oncology (acquired by Genzyme).
Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts
Altimmune is working on a developmental weight loss drug that could have strong benefits for an important segment of GLP-1 users.